About Sialidase-3
Sialidase-3 (NEU3) is a protein
from Homo sapiens identified by UniProt accession
Q9UQ49, 428 residues long.
MolForge cross-references it against 0 known binders and
86 disease associations.
Target properties
| Protein name | Sialidase-3 |
|---|
| UniProt accession | Q9UQ49 |
|---|
| Gene | NEU3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 428 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (86)
Diseases linked to this target (Open Targets).
- diabetic eye disease · score 0.12
- Rheumatoid arthritis · score 0.05
- type 2 diabetes mellitus · score 0.05
- urinary bladder carcinoma · score 0.05
- body height · score 0.04
- colitis · score 0.04
- melanoma · score 0.04
- cancer · score 0.04
- neoplasm · score 0.04
- GM1 gangliosidosis · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UQ49-F1 | alphafold | PREDICTED | 86.83 | — |
Amino-acid sequence (428 residues)
MEEVTTCSFN SPLFRQEDDR GITYRIPALL YIPPTHTFLA FAEKRSTRRD EDALHLVLRR GLRIGQLVQW GPLKPLMEAT LPGHRTMNPC PVWEQKSGCV FLFFICVRGH VTERQQIVSG RNAARLCFIY SQDAGCSWSE VRDLTEEVIG SELKHWATFA VGPGHGIQLQ SGRLVIPAYT YYIPSWFFCF QLPCKTRPHS LMIYSDDLGV TWHHGRLIRP MVTVECEVAE VTGRAGHPVL YCSARTPNRC RAEALSTDHG EGFQRLALSR QLCEPPHGCQ GSVVSFRPLE IPHRCQDSSS KDAPTIQQSS PGSSLRLEEE AGTPSESWLL YSHPTSRKQR VDLGIYLNQT PLEAACWSRP WILHCGPCGY SDLAALEEEG LFGCLFECGT KQECEQIAFR LFTHREILSH LQGDCTSPGR NPSQFKSN
Explore Sialidase-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets